Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HC101b
- Development stage
- Preclinical
- Lead developer
- HebeCell
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
HC101b is an investigational, off-the-shelf natural killer (NK) cell therapy developed by HebeCell for the treatment of acute myeloid leukemia (AML). The therapy is produced using HebeCell's proprietary ProtoNK™ platform, which employs a unique 3D feeder-free system to differentiate human induced pluripotent stem cells (iPSCs) into standardized, highly potent NK cells. Unlike traditional NK cell therapies derived from peripheral blood or umbilical cord blood, HC101b aims to provide a scalable and uniform product with enhanced cytotoxic activity against leukemic blasts. By utilizing iPSCs as a starting material, HebeCell can produce large quantities of standardized NK cells that are ready for clinical use. HC101b is currently in the preclinical stage of development.
- Other names
- ProtoNK NK cells for AMLHebeCell NK cell therapy
Beyond the preview
Go deeper on HC101b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HC101b.